Truist analyst Srikripa Devarakonda views the recent weaknes...

Truist analyst Srikripa Devarakonda views the recent weakness in Cytokinetics' stock as a buying opportunity and maintains a buy rating and $86 price target on the stock. Devarakonda continues to see Cytokinetics as a potential M&A target.